TY - JOUR
T1 - New anticoagulants for prevention of stroke in patients with atrial fibrillation
AU - Viles-Gonzalez, Juan F.
AU - Fuster, Valentin
AU - Halperin, Jonathan L.
PY - 2011/8
Y1 - 2011/8
N2 - New Anticoagulants in Atrial Fibrillation. Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using vitamin K antagonists (VKA) is currently prescribed for prevention of ischemic stroke in patients with AF. A narrow therapeutic range and frequent food and drug interactions underly the need for regular monitoring of anticoagulation intensity and impairs the utility and safety of VKA, stimulating a quest for alternative anticoagulant agents. Recently developed anticoagulants include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors rivaroxaban, apixaban, edoxaban, to name those in the most advanced stages of clinical development. This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF.
AB - New Anticoagulants in Atrial Fibrillation. Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using vitamin K antagonists (VKA) is currently prescribed for prevention of ischemic stroke in patients with AF. A narrow therapeutic range and frequent food and drug interactions underly the need for regular monitoring of anticoagulation intensity and impairs the utility and safety of VKA, stimulating a quest for alternative anticoagulant agents. Recently developed anticoagulants include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors rivaroxaban, apixaban, edoxaban, to name those in the most advanced stages of clinical development. This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF.
KW - anticoagulation
KW - atrial fibrillation
KW - dabigatran
KW - factor Xa inhibitor
KW - stroke
UR - https://www.scopus.com/pages/publications/80051800555
U2 - 10.1111/j.1540-8167.2011.02104.x
DO - 10.1111/j.1540-8167.2011.02104.x
M3 - Review article
C2 - 21668558
AN - SCOPUS:80051800555
SN - 1045-3873
VL - 22
SP - 948
EP - 955
JO - Journal of Cardiovascular Electrophysiology
JF - Journal of Cardiovascular Electrophysiology
IS - 8
ER -